Workflow
NanoPortal™ platform
icon
Search documents
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
Globenewswire· 2025-08-20 12:30
ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025 in New York, New York. Details of Dr. Mendelsohn’s presentation are as follows: D ...
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer
Globenewswire· 2025-06-11 12:00
Core Insights - Vivani Medical, Inc. has appointed Anthony Baldor as Chief Financial Officer, succeeding Brigid A. Makes, who is retiring to focus on other commitments [1][3] - Baldor has over 20 years of financial management experience in the biotechnology sector, with a strong background in fundraising and corporate strategy [2] - The CEO of Vivani, Adam Mendelsohn, expressed confidence in Baldor's expertise to advance the company's pipeline and operations during a critical period [3] Company Overview - Vivani Medical develops miniature, ultra long-acting drug implants using its proprietary NanoPortal™ platform, aimed at improving medication adherence and patient tolerance [4] - The lead program, NPM-115, is a six-month GLP-1 implant for chronic weight management, with additional products in the pipeline, including NPM-139 and NPM-119, targeting similar therapeutic areas [4] - Medication non-adherence affects approximately 50% of patients, contributing to over $500 billion in annual avoidable healthcare costs and 125,000 preventable deaths in the U.S. [4]